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Abstract
BACKGROUND: Symptoms are known to predict survival among patients with heart failure (HF), but
discrepancies exist between patients' and health providers' perceptions of HF symptom burden.
OBJECTIVE: The purpose of this study is to quantify the internal consistency, validity, and prognostic value
of patient perception of a broad range of HF symptoms using an HF-specific physical symptom measure, the
18-item HF Somatic Perception Scale v. 3.
METHODS: Factor analysis of the HF Somatic Perception Scale was conducted in a convenience sample of
378 patients with chronic HF. Convergent validity was examined using the Physical Limitation subscale of the
Kansas City Cardiomyopathy Questionnaire. Divergent validity was examined using the Self-care of HF Index
self-care management score. One-year survival based on HF Somatic Perception Scale scores was quantified
using Cox regression controlling for Seattle HF Model scores to account for clinical status, therapeutics, and
lab values.
RESULTS: The sample was 63% male, 85% white, 67% functionally compromised (New York Heart
Association class III-IV) with a mean (SD) age of 63 (12.8) years. Internal consistency of the HF Somatic
Perception Scale was α = .90. Convergent (r = -0.54, P < .0001) and divergent (r = 0.18, P > .05) validities
were supported. Controlling for Seattle HF scores, HF Somatic Perception Scale was a significant predictor of
1-year survival, with those most symptomatic having worse survival (hazard ratio, 1.012; 95% confidence
interval, 1.001-1.024; P = .038).
CONCLUSIONS: Perception of HF symptom burden as measured by the HF Somatic Perception Scale is a
significant predictor of survival, contributing additional prognostic value over and above objective Seattle HF
Risk Model scores. This analysis suggests that assessment of a broad range of HF symptoms, or those related
to dyspnea or early and subtle symptoms, may be useful in evaluating therapeutic outcomes and predicting
event-free survival.
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Abstract
Background—Symptoms are known to predict survival among patients with heart failure (HF) 
but discrepancies exist between patients’ and health providers’ perceptions of HF symptom 
burden.
Objective—The purpose of this study was to quantify the internal consistency, validity and 
prognostic value of patient perception of a broad range of HF symptoms using a HF-specific 
physical symptom measure, the 18-item HF Somatic Perception Scale v.3.
Methods—Factor analysis of the HFSPS was conducted in a convenience sample of 378 patients 
with chronic HF. Convergent validity was examined using the Physical Limitation subscale of the 
Kansas City Cardiomyopathy Questionnaire (KCCQ). Divergent validity was examined using the 
Self-Care of HF index self-care management score. One-year survival based on HFSPS scores was 
quantified using Cox regression controlling for Seattle HF Model scores to account for clinical 
status, therapeutics and lab values.
Results—The sample was 63% male, 85% Caucasian, 67% functionally compromised (NYHA 
class III-IV) with a mean age of 63, SD12.8 years. Internal consistency of the HFSPS was α =.90. 
Convergent (r=−0.54, p=<0.0001) and divergent (r=0.18, p>0.05) validity were supported. 
Controlling for Seattle HF scores, HFSPS was a significant predictor of one-year survival with 
those most symptomatic having worse survival (HR=1.012 (95%CI=1.001–1.024), p=0.038).
Conclusions—Perception of HF symptom burden as measured by the HFSPS is a significant 
predictor of survival contributing additional prognostic value over and above objective Seattle HF 
Risk Model scores. This analysis suggests that assessment of a broad range of HF symptoms, or 
those related to dyspnea or early and subtle symptoms may be useful in evaluating therapeutic 
outcomes and predicting event-free survival.
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Symptoms of heart failure (HF) drive care-seeking, healthcare utilization and predict quality 
of life and survival.1–4 Costs associated with HF are estimated to be over $30 billion 
annually and approximately half of patients with HF die within 5 years of diagnosis.5,6 The 
high costs associated with HF are in part due to the need for repetitive hospitalization for 
treatment of escalating signs and symptoms of HF.7 Patients with HF frequently experience 
multiple symptoms simultaneously8–10 potentially increasing symptom burden; the 
cumulative sum, severity and impact of symptoms on the individual.9,11 However, there is 
substantial variation in how signs and symptoms of HF are perceived and reported by 
patients. Assessment and documentation by clinicians also is variable.12–17 Therefore, 
methodically assessing patient perception of symptoms is of potential value for prediction of 
both morbidity and mortality risk in this population. Reliable and valid tools to assess both 
the presence and burden/interference associated with signs and symptoms of HF are needed 
to improve the ability to predict outcomes.
The effect of HF symptoms on survival has been investigated using measures that vary 
considerably in method and the number and type of symptoms assessed.3,4,12,18–20 For 
example, symptoms have been inferred from quality of life measures,19 HF-specific 
symptom instruments,3,4,20 study-specific questionnaires18 and from symptom dairies.12 
Timeframes for symptom recall among the various measures range from one to 30 days, and 
the number of symptoms assessed ranges from a minimum of four up to eighteen. Finally, 
the type of signs and symptoms included in these measures vary considerably in scope. In 
particular, HF symptoms that are subtle in nature or early indicators of impending 
decompensation were limited in many measures used in studies on HF symptoms and 
survival.4,12,18–20 Moreover, the measurement of dyspnea, a hallmark symptom of HF that is 
well-known to vary in intensity based on activity and illness severity, was limited to a single 
item in half of these studies12,18,19 and dyspnea on exertion was only measured in one 
study.3
Clearly, robust and sound measures are needed that assess the breadth and complexity of HF 
symptoms including hallmarks and the early and subtle symptoms of impending 
decompensation. Therefore, the purpose of this study was to quantify the internal 
consistency, validity and prognostic value of patient perception of a broad range of HF 
symptoms using a HF-specific physical symptom measure, the 18-item HF Somatic 
Perception Scale v.3.
Method
A secondary analysis was conducted of 2 convenience samples with 18-item HF Somatic 
Perception Scale v.3 (HFSPS) data; one that assessed symptoms pre-randomization in a trial 
focused on symptom management2 and one that evaluated symptoms among community-
dwelling participants of two observational studies of heart failure symptoms.3,21 Sampling 
criteria was similar between the samples. Inclusion criteria included (a) a confirmed 
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diagnosis of HF, (b) able to read and comprehend fifth grade English, (c) reachable by 
telephone, (d) absence of major cognitive impairment, and (e) willing and able to provide 
informed consent. Exclusion criteria included (a) major uncorrected hearing impairment, (b) 
major psychiatric illness (e.g. schizophrenia), (c) major uncorrected visual impairment, (d) 
not expected to live for months, and (e) reversible HF (e.g. HF due to high output states). 
Human subjects approval was secured from each of the principal investigator’s institutions.
Measurement
Physical HF symptoms were measured using the HFSPS, V.3, an 18-item Likert scale. The 
original scale22 was expanded from 12 items to 18 to capture the more subtle symptoms of 
HF. Importantly, the development of the original HFSPS and this current 18 item version 
were guided by Lenz’s Theory of Unpleasant Symptoms, with respect to interactions among 
multiple symptoms, multiple influential pathophysiological mechanisms, situational factors, 
and performance (e.g. HRQOL and clinical event-risk).23,24 Additional items were added to 
assess dyspnea on exertion, fatigue, nocturia, and symptoms associated with right-sided 
congestion (i.e. abdominal swelling and loss of appetite).25 The HFSPS asks participants 
how much they are bothered by symptoms in the past week using 5 response options ranging 
from 0 (I did not have the symptom) to 5 (extremely bothersome). Scores are summed with 
higher values indicating higher symptom burden.
Convergent validity provides evidence of validity by examining the correlation between 
different measures of a construct. To support convergent validity, correlation of theoretically-
related construct measures should be high.26,27 The Kansas City Cardiomyopathy 
Questionnaire (KCCQ) is a 23-item Likert scale health status measure that assesses physical 
function, symptoms, social function, self-efficacy, and quality of life among patients with 
HF.28 The KCCQ is a reliable and valid measure of health status responsive to change 
clinical status. The 6-item Physical Limitation subscale of the (KCCQ) was used to examine 
convergent validity. Scores range 1 to 36 on the Physical Limitation subscale. Higher scores 
indicate better function. The reliability of the Physical Limitation subscale is acceptable with 
a Cronbach’s alpha of 0.90. We hypothesized that the correlation between the HFSPS and 
KCCQ Physical Limitation subscale would be significant.
Discriminant validity examines differentiation of constructs that are theoretically different. 
To support discriminant validity, correlation between two different constructs should be 
low.26,27 The Self-Care of HF Index (SCHFI) was used to quantify self-care.29 The SCHFI 
v.6.2 is a 22-item scale using a 4-point self-report response format to measure self-care 
maintenance (adherence behaviors), self-care management (response to symptoms) and self-
care confidence. The 6-item Self-Care Management score was used to examine discriminant 
validity for this analysis because it reflects how quickly participants recognized and 
responded symptoms as opposed to the physical experience of symptoms. Symptom 
recognition options ranged from 0 (I did not recognize it as a symptom of HF) to 4 (very 
quickly). Response to symptoms options included rating the likelihood of taking action to 
manage symptoms (e.g. taking an extra diuretic, reducing fluid intake) from 1 (not likely) to 
4 (very likely). Scores are standardized to range from 0 to 100 with higher values indicated 
better symptom response behaviors. The Self-Care Management subscale of the SCHFI is 
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multidimensional with a two factor structure representing symptom evaluation and treatment 
implementation. Therefore, a global reliability index is used to assess internal consistency. 
The global reliability index derived from the weighted least squares means and variance is 
0.77 and 0.76 respectively.30 We hypothesized that the correlation between the HFSPS and 
SCHFI Self-Care Management subscale would be weak and insignificant.
We completed a review of the electronic medical record at 1 year looking specifically for 
HF-related emergency room visits, hospitalizations or mortality. For the vast majority of 
events data were extracted directly from discharge summaries all participants received care 
locally and were part of an extensively-linked electronic medical record system. We also 
contacted study participants by phone to inquire about events that occurred outside of the 
health system network; we solicited sufficient detail directly from participants or their 
family members to determine whether or not the event was primarily related to their HF or 
for other reasons. All events underwent adjudication by two separate evaluators until 100% 
agreement was reached about the underlying reasons for emergent healthcare utilization.
Analysis
HFSPS item response means and standard deviations, and average inter-item correlations 
(i.e. the mean of all paired correlations between items) were quantified.31 Item difficulty was 
assessed by quantifying the proportion of participants who provided the best possible 
response (I did not have this symptom). Item difficulty of 0.3 indicates that many (70%) 
participants had difficulty with the symptom, and item difficulty of 0.7 indicates that few 
(30%) participants had difficulty with the symptom; between 0.3 and 0.7 is the best range for 
item difficulty. Item discrimination was quantified by comparing item difficulty between 
participants with HFSPS total scores in the top and bottom thirds of the distribution.
Confirmatory factor analysis was performed using Mplus v.6 (Los Angeles, California). 
Geomin (oblique) rotation was chosen for this analysis using weighted least square 
parameter estimation with mean-and variance-adjusted statistics. Results are presented in 
rotated factor loadings and standard errors. To assess model fit, overall model χ2 tests, 
comparative fit indices (CFI), Tucker-Lewis indices (TLI), root mean square errors of 
approximation (RMSEA), standardized root mean square residuals (SRMSR), normed fit 
index (NFI), and adjusted goodness-of-fit index (AGFI) were calculated using common 
thresholds of acceptability.32 As the HFSPS was developed as a unidimensional scale, 
Cronbach’s alpha was calculated as an index of internal consistency.
Pearson’s correlations were used to quantify convergent (KCCQ physical limitations score) 
and discriminant validity (SCHFI Self-Care Management). Finally, Cox proportional 
hazards modeling was performed using Stata MP v13 (College Station, TX) to quantify 1-
year HF event-risk (emergency room visit or hospitalization for HF or all-cause death) as a 
function of the HFSPS scores. The proportional hazards assumption was justified based on 
Schoenfeld residuals. Hazard ratios (HR) and 95% confidence intervals (CI) are presented. 
To account for the influence of many other factors, the influence of symptom profiles on 
event-free survival was adjusted for the Seattle HF Score. The Seattle HF Score was 
calculated based on the original model developed by Levy and colleagues.33 In brief, 
demographic (i.e. age, gender) objective clinical indices (i.e. ischemic etiology, NYHA 
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functional class, left ventricular ejection fraction, systolic blood pressure, hemoglobin, % 
lymphocyte count, uric acid, sodium, cholesterol) and HF treatment (i.e. beta blocker, 
angiotensin converting enzyme inhibitor, allopurinol, diuretic dose, statin use, and device 
therapy) were multiplied by respective slope coefficients33 to generate a single composite 
risk-prediction score that in this sample ranged from −0.16 to 3.34.
Results
The samples used in this psychometric analysis are presented in Table 1. In brief, the sample 
was predominantly male (63.2%), Caucasian (85.2%) older adults (mean age = 62.6±12.8 
years). A majority of participants (67.2%) had NYHA class III/IV symptoms.
Item Responses
Fatigue was the most commonly reported symptom (item difficulty = 0.09) and paroxysmal 
nocturnal dyspnea was the least commonly reported symptom (item difficulty = 0.66) (Table 
2). Average inter-item correlations on the HFSPS were consistent and ranged from 0.32 (It 
was hard for me to breath) to 0.35 (I had a cough) indicating that removing single items 
would not likely improve internal consistency. Most items were discriminatory regarding the 
top and bottom 33.3% of physical HF symptom burden. In contrast, having a cough, being 
tired, and waking up at night to urinate were not helpful in discriminating between 
participants who reported least versus most burdensome physical HF symptoms because 
they were either highly-prevalent or because they were relatively normally distributed across 
response options.
Factor Analyses
The confirmatory factor analysis of the HFSPS is presented in Table 3. Several fit indices 
reached and others were close to reaching thresholds of acceptability; thus, the fit of the 
HFSPS as a single scale could be improved. The best fit exploratory factor analysis of the 
HFSPS, based on fit statistics and thresholds of acceptability, is also presented in Table 3. 
The resulting subscales were labeled according to dominant features as “dyspnea,” “chest 
discomfort,” “early and subtle” and “edema.” Considering these four factors, the fit of the 
HFSPS was improved considerably.
Internal Consistency
Cronbach’s alpha of the 18-item HFSPS was 0.90. Single item deletion did not result in 
significant improvement of internal consistency. Cronbach’s alpha was 0.89 on the 6-item 
dyspnea subscale. Cronbach’s alpha was 0.75 on the 7-item “early and subtle” subscale. 
Cronbach’s alpha was 0.75 and 0.68 on the edema and chest discomfort subscales, 
respectively; but, these scales contain too few items for meaningful analysis.
Convergent and Divergent Validity
Convergent validity testing of the HFSPS with the KCCQ Physical Limitations score, and 
discriminant validity testing of the HFSPS with the SCHFI Self-Care Management are 
presented in Table 4. There were strong correlations between both the HFSPS and subscales 
and the KCCQ Physical Limitations score indicating similarity between measures of 
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theoretically-related constructs. The HFSPS and subscales were not correlated with SCHFI 
Self-Care Management score confirming discriminant validity. Convergent and discriminant 
validity testing was limited to the total HFSPS and subscales for “dyspnea” and “early and 
subtle” subscales because the “chest discomfort” and “edema” subscales had few items.
Predictive Validity
The results of predictive validity testing are presented in Table 5. The 18-item HFSPS, 6-
item dyspnea subscale, and 7-item early and subtle subscale were significantly associated 
with 1-year event-risk when controlling for the Seattle HF Score. Survival curves depicting 
event-free survival differences across a gradient of physical symptoms by HFSPS tertiles are 
presented in Figure 1. The severe symptom tertile is associated with markedly increased risk 
of HF-related clinical risks compared with the low symptom tertile on the 18-item HFSPS 
(HR=1.65, p=0.048), 6-item dyspnea subscale (HR=1.70, p=0.029) and 7-item early and 
subtle subscale (HR=1.99, p=0.010).
Discussion
The HFSPS is a valid and reliable measure of HF symptom perception and burden in this 
sample of 378 adults with symptomatic HF. The HFSPS total, “dyspnea” and “early and 
subtle” subscale scores were associated significantly with a measure of physical limitations, 
and predicted HF event-free survival independent of a commonly used prognostication 
model.33 Thus, the analysis indicates that patient perception of the physical symptoms of HF 
adds value when predicting clinical events.
The “dyspnea subscale” is a robust subscale with good reliability and validity that examines 
a broad range and severity of dyspnea symptoms related to HF. We found that the dyspnea 
subscale was effective in predicting HF-related clinical events. Clinical events were 
adjudicated for HF specific events in this study. Conversely, dyspnea did not predict HF-
related hospitalizations in the study by Ekman.18 However, only two dyspnea symptoms 
were assessed and one (orthopnea) was assessed as present or absent. Similarly, dyspnea did 
not predict cardiac events in the study by K. Lee and colleagues.19 A potential explanation 
of is that dyspnea was limited to one item and clustered with fatigue and sleep disturbance in 
the survival analysis. The flexibility of using the HFSPS dyspnea subscale is of interest for 
clinical and research use.
Importantly, assessment of the early and subtle symptoms of HF has clinical value. We 
found that increased severity of the early and subtle HF symptoms is associated with almost 
two times the risk of a clinical event within one year. Fatigue as a singular symptom 
(RR=1.09, p=0.018)18 or clustered with other early and subtle symptoms (HR=1.00, 
p=0.011)4 was a significant predictor of HF event risk in other studies. Accordingly, there 
are important implications of this finding for both patients and health care providers. First, 
patients often have difficulty recognizing and responding to escalation in burden of the 
subtle nonspecific symptoms of HF.14,34 Patients normalize and adjust to chronic symptoms 
decreasing symptom interference on daily living.14 However, lack of attention to early and 
subtle signs of decompensation may contribute to delay in self-management and or care-
seeking.14 Patients with HF are typically instructed to monitor daily weights as an objective 
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measure of increasing congestion. However, a disassociation between weight and dyspnea 
has been reported potentially increasing the importance of assessing additional symptom 
parameters.35–37 Second, among patients with HF, cognitive impairment is common, can be 
subtle, and potentially impedes symptom reporting.38–40 Despite the prevalence of cognitive 
impairment in this population, it is infrequently documented in the medical record by health 
care providers.41 Therefore, educating patients regarding the importance of monitoring the 
early and subtle symptoms of HF that are commonly attributed to less threatening illness is 
warranted. In addition, involving family and significant others in the education may improve 
effectiveness in detecting insidious increases in symptom severity. Taken together, evidence 
suggests that assessment of a broad range of HF symptoms may be useful in evaluating 
therapeutic outcomes, predicting survival, and informing clinical decision making.
Strengths and Limitations
There are several strengths and limitations to be considered in interpreting these results. 
Strengths of this analysis lie in use of a HF-specific symptom scale and prospective 
documentation of symptom burden. Use of the HFSPS also afforded assessment of a broad 
range of symptoms including those potentially not reported by patients unless specifically 
asked. The survival analysis was strengthened by adjusting for clinical and treatment 
variables known to influence survival.
Limitations include a primarily male Caucasian sample limiting generalizability of the 
findings. In addition, the fit indices in this analysis were not perfect, but very good by most 
metrics. Although survival analyses are robust with smaller samples, additional testing of the 
predictive validity of the HFSPS and subscales is needed. Future testing also is needed to 
examine differential item functioning by gender, race, ethnicity and other factors.
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Table 1
Characteristics of the sample (n=378)
Sample 1 (n=105) Sample 2 (n=273) Full Sample (n=378)
Patient Characteristics: mean±SD, n (%),
median [IQR]
mean±SD, n (%),
median [IQR]
mean±SD, n (%),
median [IQR]
Age (years) 67.9±12.3 57.3±13.2 62.6±12.8
Female 33 (31.4%) 106 (38.8%) 139 (36.8%)
Non-Hispanic Caucasian 93 (88.6%) 229 (83.9%) 322 (85.2%)
Married/Living with Partner 62 (59.1%) 173 (63.4%) 235 (62.2%)
Charlson Comorbidity Index (weighted) 3.1±1.5 2.3±1.4 2.5±1.3
General Heart Failure Characteristics:
Time with heart failure in months: 48 [12–102] 49 [16–96] 49 [14–98]
NYHA Functional Class:
 Class I/II 17 (16.3%) 106 (38.8%) 123 (32.5%)
 Class III 48 (46.2%) 157 (57.64%) 205 (54.2%)
 Class IV 39 (37.5%) 10 (3.7%) 49 (13.0%)
Left ventricular ejection fraction (%) 37.5±16.8 28.3±12.4 32.8±14.0
Prescribed a β-blocker 91 (86.7%) 248 (90.8%) 339 (89.7%)
Prescribed an ACE-I or ARB 64 (61%) 223 (81.7%) 287 (75.9%)
Serum sodium (mEq/L) 138.9±3.8 137.8±3.3 138.3±3.4
Serum BUN-to-creatinine ratio (mg/dL:1) 23.6±8.8 20.2±9.5 21.8±9.1
Abbreviations: ACE-I = Angiotensin Converting Enzyme-Inhibitor, ARB = Angiotensin Receptor Blocker, BUN = blood urea nitrogen, IQR = 
interquartile range, NYHA = New York Heart Association, SD = standard deviation.
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Table 4
Convergent and Divergent Validity for the Heart Failure Somatic Perception Scale
Linear correlations KCCQ Physical Limitations SCHFI Self-Care Management
HFSPS
−0.544† 0.181
HFSPS dysnea
−0.529† 0.182
HFSPS early
−0.390† 0.106
†p<0.0001 for all correlations with Bonferroni correction for multiple measures
Abbreviations: HFSPS = Heart Failure Somatic Perception Scale; KCCQ = Kansas City Cardiomyopathy Questionnaire; SCHFI = Self-Care of 
Heart Failure Index (v6).
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Table 5
Predictive Validity for the Heart Failure Somatic Perception Scale
365-day Adjusted Hazard Ratio† 95%CI p-value
HFSPS 1.012 1.001–1.024 0.038
HFSPS dyspnea 1.031 1.003–1.060 0.031
HFSPS early 1.030 1.003–1.058 0.028
†
adjusted for the Seattle Heart Failure Score
Abbreviations: HFSPS = Heart Failure Somatic Perception Scale
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